APF is Recipient of Second Annual Advocacy for Impact Grants Program

Alnylam Pharmaceuticals, Inc., announced this week that the APF is one of seven patient advocacy groups will receive supportive funding as part of the company’s second annual Advocacy for Impact grants program.

The global competitive grants program aims to inspire patient advocacy groups to develop solutions that address critical unmet needs among the hereditary transthyretin-mediated (hATTR) amyloidosis, acute hepatic porphyria (AHP) and primary hyperoxaluria type 1 (PH1) rare disease communities.

The 2019-2020 Advocacy for Impact grants program was open to patient advocacy groups around the world requesting funding for up to $50,000 for new projects focused on supporting the hATTR amyloidosis, AHP and/or PH1 communities in one of the following ways:

• Increase disease awareness and access to diagnosis
• Offer education to patients, families, caregivers, healthcare providers and/or public
• Improve patient care

Click Here to Read the Alnylam Press Release